• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2025.20064

Kidney condition in rheumatoid arthritis

[Reviews]
Nadezhda Yurievna Tikhomirova;

The incidence of chronic rheumatological diseases (rheumatoid arthritis, in particular) has increased over the past decade. In rheumatoid arthritis, in addition to the musculoskeletal system, internal organs (kidneys, heart, blood vessels) are also affected. The review analyzes the kidney condition in rheumatoid arthritis by conducting a study of published research results using the PubMed search engine, e-library over the past 10 years. The results obtained during the analysis of the articles indicate a high prevalence of chronic kidney disease among patients with rheumatoid arthritis, the peculiarities of the effect of these conditions on diseases of the cardiovascular system, and early markers of kidney damage. These data may be relevant for finding strategies for nephroprotective therapy in patients with rheumatoid arthritis

Download

References:
1. Guan S. Y., Zheng J. X., Sam N. B., Xu S., Shuai Z. [et al.]. Global burden and risk factors of musculoskeletal disorders among adolescents and young adults in 204 countries and territories, 1990-2019. Autoimmun. Rev. 2023;22(8):103361. https://doi.org/10.1016/j.autrev.2023.103361
2. Axmedjanova N. I., Axmedjanov I. A., Ismailova Z. A.,Gapparova G. N. Evaluation of Kidney Functioning in Children with Renal Complications During COVID-19 Pandemic: A Retrospective Observational Cohort Clinical Study. Kubanskij nauchnyj Medicinskii vestnik. – Kuban Scientific Medical Bulletin. 2023;30(3):25-33. (In Russ.). https://doi.org/10.25207/1608-6228-2023-30-3-25-33
3. Nagy G., Roodenrijs N. M. T., Welsing P. M., Kedves M., Hamar A. [et al.]. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann. Rheum. Dis. 2021;80(1):31-35. https://doi.org/10.1136/annrheumdis-2020-217344
4. Yoshimura Y., Yamanouchi M., Mizuno H., Ikuma D., Koizumi R. [et al.]. Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease. Ann. Rheum. Dis. 2024;83(10):1278-1287. https://doi.org/10.1136/ard-2024-225914
5. Fukui S., Winkelmayer W. C., Tedeschi S. K., Marrugo J., Guan H. [et al.]. Disease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study. Ann. Rheum. Dis. 2025;84(2):201-209. https://doi.org/10.1136/ard-2024-226156
6. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133-2161. https://doi.org/10.1016/S0140-6736(24)00757-8
7. Märker-Hermann E. Nieren manifestation enbeirheumatoider Arthritis und Spondyloarthrit iden Renal manifestations in rheumatoid arthritis and spondylarthritis. Z. Rheumatol. 2022;81(10):845-850. https://doi.org/10.1007/s00393-022-01279-1
8. Kapoor T., Bathon J. Renal Manifestations of Rheumatoid Arthritis. Rheum. Dis. Clin. North. Am. 2018;44(4):571-584. https://doi.org/10.1016/j.rdc.2018.06.008
9. Chebotareva N. V., Gulyaev S. V., Androsova T. V., Popova E. N., Gurova D. V. [et al.]. Clinicopatological variants and risk factors for chronic kidney disease in rheumatoid arthritis. Terapevticheskii Arkhiv. – Ter. Arkh. 2020;92(5):55-60. (In Russ.). https://doi.org/10.26442/00403660.2020.05.000604
10. Puthumana J., Thiessen-Philbrook H., Xu L., Coca S. G., Garg A. X. [et al.]. Biomarkers of inflammation and repair in kidney disease progression. J. Clin. Invest. 2021;131(3):e139927. https://doi.org/10.1172/JCI139927
11. Iversen E., Walls A. B., Petersen A., Jensen P. S., Kallemose T. [et al.]. Estimated glomerular filtration rate based on creatinine, cystatin C, β-trace protein and β2 microglobulin in patients undergoing nontraumatic lower extremity amputation. Br. J. Clin. Pharmacol. 2023;89(6):1789-1798. https://doi.org/10.1111/bcp.15639
12. Guszcz T., Sankiewicz A., Gałek L., Chilinska-Kopko E., Hermanowicz A. [et al.]. Application of Surface Plasmon Resonance Imaging Biosensors for Determination of Fibronectin, Laminin-5, and Type IV Collagen in Plasma, Urine, and Tissue of Renal Cell Carcinoma. Sensors (Basel). 2024;24(19):6371. https://doi.org/10.3390/s24196371
13. Kalmykova A. S., Abdullina A. E. Rol’ kollagena IV tipa v razvitii diabeticheskoj nefropatii pri saharnom diabete 1 tipa. Medicinskii vestnik Severnogo Kavkaza. – Medical News of North Caucasus. 2020;15(4):600-604. (In Russ.). https://doi.org/10.14300/mnnc.2020.15143
14. Okasha K. M., Aboufreikha M. H., Elrefaey W., Ashmawy M. M., Mourad H. [et al.]. Association of Serum Osteoprotegerin Level with Myocardial Injury and Cardiovascular Calcification in Chronic Kidney Disease Patients. Front. Med. (Lausanne). 2022;9:814970. https://doi.org/10.3389/fmed.2022.814970
15. Sevinc C., Yilmaz G., Ustundag S. The Relationship between Calcification Inhibitor Levels in Chronic Kidney Disease and the Development of Atherosclerosis. Ren. Fail. 2021;43(1):1349-1358. https://doi.org/10.1080/0886022X.2021.1969248
16. Lee J. S., Oh J. S., Kim Y. G., Lee C. K., Yoo B. [et al.]. Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction. Rheumatol. Int. 2020;40(5):765-770. https://doi.org/10.1007/s00296-020-04547-y
17. Kalantar-Zadeh K., Jafar T. H., Nitsch D., Neuen B. L., Perkovic V. Chronic kidney disease. Lancet. 2021;398(10302):786-802. https://doi.org/10.1016/S0140-6736(21)00519-5
18. Paudyal S., Yang F. M., Rice C., Chen С. С., Skelton М. [et al.]. End-stage renal disease in patients with rheumatoid arthritis. Semin. Arthritis Rheum. 2017;46(4):418-422. https://doi.org/10.1016/j.semarthrit.2016.07.016
19. Jadoul M., Aoun M., Masimango Imani M. The major global burden of chronic kidney disease. Lancet Glob. Health. 2024;12(3):e342-e343. https://doi.org/10.1016/S2214-109X(24)00050-0
20. Carney E. F. The impact of chronic kidney disease on global health. Nat. Rev. Nephrol. 2020;16(5):251. https://doi.org/10.1038/s41581-020-0268-7
21. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-733. https://doi.org/10.1016/S0140-6736(20)30045-3
22. Evans M., Lewis R. D., Morgan A. R., Whyte M. B., Hanif W. [et al.]. A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives. Adv. Ther. 2022;39(1):33-43. https://doi.org/10.1007/s12325-021-01927-z
23. Lee C. L., Liu W. J., Tsai S. F. Development and validation of an insulin resistance model for a population with chronic kidney disease using a machine learning approach. Nutrients. 2022;14(14):2832. https://doi.org/10.3390/nu14142832
24. Ridker P. M., Devalaraja M., Baeres F. M. M., Engelmann M. D. M., Hovingh G. K. [et al.]. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebocontrolled, phase 2 trial. Lancet. 2021;397(10289):2060-2069. https://doi.org/10.1016/S0140-6736(21)00520-1
25. Uludag K., Boz G., Arikan T., Gunal A. I. Temporal evolution of C-reactive protein levels and its association with the incident hospitalization risk among individuals with stage 3-4 chronic kidney disease. Int. Urol. Nephrol. 2022;54(3):609-617. https://doi.org/10.1007/s11255-021-02935-2
26. He P., Zhang J., Tian N., Deng Y., Zhou M. [et al.]. The relationship between C-reactive protein to lymphocyte ratio and the prevalence of chronic kidney disease in US adults: a cross-sectional study. Front. Endocrinol. (Lausanne). 2025;15:1469750. https://doi.org/10.3389/fendo.2024.1469750
27. Zhang Y., Xing Z., Zhou K., Jiang S. The predictive role of systemic inflammation response index (SIRI) in the prognosis of stroke patients. Clin. Interv. Aging. 2021;16:1997-2007. https://doi.org/10.2147/CIA.S339221
28. Wang J., Zhu Q. W., Cheng X. Y., Sha C. X., Cui Y. B. Clinical significance of neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in women with hyperglycemia. Postgrad. Med. 2020;132(8):702-708. https://doi.org/10.1080/00325481.2020.1764235
29. Zhao S., Dong S., Qin Y., Wang Y., Zhang B. [et al.]. Inflammation index SIRI is associated with increased allcause and cardiovascular mortality among patients with hypertension. Front. Cardiovasc. Med. 2022;9:1066219. https://doi.org/10.3389/fcvm. 2022.1066219
30. Kong F., Huang J., Xu C., Huang T., Wen G. [et al.]. System inflammation response index: a novel inflammatory indicator to predict all-cause and cardiovascular disease mortality in the obese population. Diabetol. Metab. Syndr. 2023;15(1):195. https://doi.org/10.1186/s13098-023-01178-8
31. Jin B., Hu W., Su S., Xu H., Lu X. [et al.]. The prognostic value of systemic inflammation response index in cholangiocarcinoma patients. Cancer Manag. Res. 2021;13:6263-6277. https://doi.org/10.2147/CMAR.S317954
32. Wang X., Ni Q., Wang J., Wu S., Chen P. [et al.]. Systemic inflammation response index is a promising prognostic marker in elderly patients with heart failure: a retrospective cohort study. Front. Cardiovasc. Med. 2022;9:871031. https://doi.org/10.3389/fcvm.2022.871031
33. Chao B., Ju X., Zhang L., Xu X., Zhao Y. A novel prognostic marker systemic inflammation response index (SIRI) for operable cervical cancer patients. Front. Oncol. 2020;10:766. https://doi.org/10.3389/fonc.2020.00766
34. Wei L., Mao S., Liu X., Zhu C. Association of systemic inflammation response index with all-cause mortality as well as cardiovascular mortality in patients with chronic kidney disease. Front. Cardiovasc. Med. 2024;11:1363949. https://doi.org/10.3389/fcvm.2024.1363949
35. Huang P., Mai Y., Zhao J., Yi Y., Wen Y. Association of systemic immune-inflammation index and systemic inflammation response index with chronic kidney disease: observational study of 40,937 adults. Inflamm. Res. 2024;73(4):655-667. https://doi.org/10.1007/s00011-024-01861-0
36. Yin X., Zhang Y., Zou J., Yang J. Association of the systemic immune-inflammation index with all-cause and cardiovascular mortality in individuals with rheumatoid arthritis. Sci. Rep. 2024;14(1):15129. https://doi.org/10.1038/s41598-024-66152-4
37. Hanaoka H., Kikuchi J., Hiramoto K., Saito S., Kondo Y. [et al.]. Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying antirheumatic drugs. Clin. Kidney J. 2022;15(7):1373-1378. https://doi.org/10.1093/ckj/sfac036
38. Smolen J. S., Landewé R. B. M., Bijlsma J. W. J., Burmester R. G., Dougados M. [et al.]. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 2020;79:685-699. https://doi.org/10.1136/ard-2022-223356corr1
39. Takanashi S., Kaneko Y., Takeuchi T. Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice. Rheumatology (Oxford). 2021;60:5247-5256. https://doi.org/10.1093/rheumatology/keab209
40. Takanashi S., Kaneko Y., Takeuchi T. CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice. Ann. Rheum. Dis. 2020;79:671-674. https://doi.org/10.1136/annrheumdis-2019-216607 41. Raj R., Thomas S., Gorantla V. Accelerated atherosclerosis in rheumatoid arthritis: a systematic review. F1000 Research. 2022;27:11:466. https://doi.org/10.12688/f1000research.112921.2
42. Charles-Schoeman C., Buch M. H., Douga-dos M., Bhatt D. L., Giles J. T. [et al.]. Risk of major adverse cardiovascular events with tofacitinib versus tumournecrosis factor inhibitors in patients withrheumatoid arthritis with or without a history ofatherosclerotic cardiovascular disease: a post hocanalysis from ORAL Surveillance. Ann. Rheum. Dis. 2023;82(1):119-129. https://doi.org/10.1136/ard-2022-222259
43. Yu K. H., Chen H. H., Cheng T. T., Jan Y. J., Weng M. Y. [et al.]. Consensus recommendations on managing the selected comorbidities including cardio-vascular disease osteoporosis, and interstitial lung disease in rheumatoid arthritis. Medicine (Baltimore). 2022;101(1):e28501. https://doi.org/10.1097/MD.0000000000028501
44. Otarova Zh. Z., Eliseeva L. N., Zhdamarova O. I., Blednova A. U., Davydova A. V. Ocenka pochechnoj gemodinamiki u bol’nyhrevmatoidnym artritom s nalichiem I bez arterial’noj gipertenzii. Kubanskij nauchnyj medicinskij vestnik. – Kuban Scientific Medical Bulletin. 2018;25(1):88-93. (In Russ.). https://doi.org/10.25207/1608-6228-2018-25-1-88-93
45. Ezeanuna M. N., Prince D. K., Alexander S. A., Richards J. S., Kerr G. S. [et al.]. Association of rheumatoid arthritis with mortality in chronic kidney disease: a cohort study. Clin. Rheumatol. 2022;41(9):2669-2676. https://doi.org/10.1007/s10067-022-06223-x
46. Paudyal S., Waller J. L., Oliver A., Le B., Zleik N. [et al.]. Rheumatoid Arthritis and Mortality in End Stage Renal Disease. J. Clin. Rheumatol. 2020;26(2):48-53. https://doi.org/10.1097/RHU.0000000000000916

Keywords: rheumatoid arthritis, chronic kidney disease, inflammation, nephroprotection